Product Images Sertraline

This is a prescription drug called Sertraline 50mg, which comes in a pack of 30 tablets. The NDC number is 84205-965-30 and the expiration date of the medication is November 2016. The lot number is G310689.*

This medication is Sertraline 50mg sold in a bottle of 90 tablets. The NDC number is 64205-965-90 and its expiration date is 11/2018. The lot number is G310889.*

The text appears to be a table showing the most common treatment-emergent adverse events and their incidence in placebo-controlled clinical trials. The table is divided by different body system adverse events schemes, such as the autonomic nervous system and psychiatric disorders. The percentage of patients reporting each event is also provided.*

This document seems to be a chart or a table with a list of medical disorders or adverse events possibly related to the medication PADD used for Social Anxiety Disorder. The first row contains the title, "PADD Social Anxiety Disorder," while the subsequent rows contain different types of disorders such as Autonomic Nervous System Disorders, Somnolence, Tremor, Dry Mouth, etc, and their respective occurrence rates in a placebo-controlled clinical trial. Some of the symptoms measured include sweating, dizziness, constipation, loss of appetite among others.*

The text describes a Table 3 that shows the incidence of treatment-emergent adverse events in placebo-controlled clinical trials for various mental health disorders such as major depressive disorder, OCD, panic disorder, PTSD, PMDD, and social anxiety disorder. The table also shows the percentage of patients reporting each event for various body systems such as autonomic nervous system disorders, central and peripheral nervous system disorders, disorders of skin and appendages, gastrointestinal disorders, general disorders, and psychiatric disorders. The adverse events include ejaculation failure, mouth dryness, increased sweating, somnolence, dizziness, headache, paresthesia, tremor, rash, anorexia, constipation, diarrhea/loose stools, dyspepsia, nausea, vomiting, fatigue, agitation, anxiety, insomnia, decreased libido, nervousness, and abnormal vision.*

This appears to be the table showing the most common adverse events associated with discontinuation in placebo-controlled clinical trials for various mental health conditions such as Major Depressive Disorder, Premenstrual Dysphoric Disorder, PTSD, Anxiety Disorder, etc. The table lists the percentages of patients who discontinued the trials due to adverse events. However, it is not clear what the values represent in the column headings as there are missing characters and symbols.*